EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.
暂无分享,去创建一个
G. Ott | M. Faehling | S. Kuom | R. Eckert | J. Sträter | T. Kamp | W. Spengler | U. Griese